ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials

Lu, Hong-Lian; Jie, Guang-Ling; Wu, Yi-Long*广东省人民医院
EXPERT OPINION ON EMERGING DRUGS2022-4-3DOI: 10.1080/14728214.2022.2063836
13阅读
引用收藏
分享

摘要

Introduction: Epidermal growth factor receptor (EGFR) is one of the most common driver gene mutations in non-small-cell lung cancer (NSCLC). EGFR-tyrosine kinase inhibitors (TKIs) monotherapy and EGFR-TKI combined with chemotherapy or anti-angiogenesis drugs have significantly prolonged the survival of patients with EGFR-mutant NSCLC. However, disease progression caused by acquired resistance to EGFR-TKIs is inevitable. And patients with EGFR exon 20ins showed limited efficacy to EGFR-TKIs. @@@ Areas covered: In this review, we initially evaluated the efficacy of existing treatments for EGFR-mutant NSCLC. Second, we reviewed the ongoing phase II and III clinical trials, provided the latest results, discussed the scientific rationale of these trials and the potential development issues. @@@ Expert opinion: The application of EGFR-TKIs has greatly changed the therapeutic strategies for advanced and resected NSCLC with EGFR mutations, and the 5-year overall survival (OS) rate for advanced NSCLC was close to 40%. The current research direction for the treatment of patients with EGFR mutations focuses on the following three aspects: uncommon EGFR mutation subtypes, brain metastases, and EGFR TKI-based combination therapy. Future studies on EGFR-mutant NSCLC therapy will focus on overcoming EGFR-TKI-related resistance, preventing drug resistance in advance, and developing bispecific antibody drugs.

学科与关键词

关键词
NSCLCEGFRtargeted therapyclinical trials
相关
加载中…
  • Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
    Li, Yang-Si; Jie, Guang-Ling; Wu, Yi-Long*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231193726.
  • Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer
    Zhou, Jia-Ying; Liu, Si-Yang; Wu, Yi-Long*Expert Opinion On Drug Safety, 2020, 19(5): 589-599.被引 12
  • EGFR抑制剂治疗EGFR突变型晚期非小细胞肺癌的Meta分析
    张蓉; 陈薇雅; 甘洁民; 赵虎; 顾兆祥检验医学, 2013, (06): 506.
查看全部 →

发表信息

论文状态
公开发表
期刊
EXPERT OPINION ON EMERGING DRUGS
发表日期
2022-04-03
卷期
第 27 卷, 第 2 期
页码
111-126
DOI
10.1080/14728214.2022.2063836
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Key Lab System Project of Guangdong Science and Technology Department, Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]

作者

  • L

    Lu, Hong-Lian (第一作者)

    guangdong prov peoples hosp

  • J

    Jie, Guang-Ling

    guangdong prov peoples hosp

查看全部 3 位作者收起作者
  • W

    Wu, Yi-Long (通讯)

    guangdong prov peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417